HALO logo

Halozyme Therapeutics (HALO) Cash From Investing

Annual CFI

-$262.72 M
-$165.81 M-171.10%

December 31, 2024


Summary


Performance

HALO Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherHALOcash flowmetrics:

Quarterly CFI

$29.48 M
+$196.96 M+117.60%

December 31, 2024


Summary


Performance

HALO Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherHALOcash flowmetrics:

TTM CFI

-$262.72 M
+$37.77 M+12.57%

December 31, 2024


Summary


Performance

HALO TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherHALOcash flowmetrics:

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

HALO Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-171.1%0.0%0.0%
3 y3 years+35.3%+135.3%-190.7%
5 y5 years-4634.6%+135.3%-190.7%

HALO Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-171.1%+46.0%-46.4%+106.8%-3216.4%+67.2%
5 y5-year-435.3%+46.0%-49.6%+106.8%-435.3%+67.2%
alltimeall time-435.3%+46.0%-49.6%+106.8%-305.1%+67.2%

Halozyme Therapeutics Cash From Investing History

DateAnnualQuarterlyTTM
Dec 2024
-$262.72 M(+171.1%)
$29.48 M(-117.6%)
-$262.72 M(-12.6%)
Sep 2024
-
-$167.48 M(+298.4%)
-$300.49 M(+38.8%)
Jun 2024
-
-$42.04 M(-49.2%)
-$216.46 M(+81.2%)
Mar 2024
-
-$82.68 M(+897.2%)
-$119.43 M(+23.2%)
Dec 2023
-$96.91 M(-80.1%)
-$8.29 M(-90.1%)
-$96.91 M(+7.2%)
Sep 2023
-
-$83.45 M(-251.7%)
-$90.36 M(+1040.7%)
Jun 2023
-
$54.99 M(-191.4%)
-$7.92 M(-98.4%)
Mar 2023
-
-$60.16 M(+3345.7%)
-$497.86 M(+2.2%)
Dec 2022
-$487.00 M(+19.9%)
-$1.75 M(+73.2%)
-$487.00 M(-37.9%)
Sep 2022
-
-$1.01 M(-99.8%)
-$784.73 M(-2.0%)
Jun 2022
-
-$434.95 M(+782.2%)
-$800.67 M(+95.1%)
Mar 2022
-
-$49.30 M(-83.5%)
-$410.34 M(+1.0%)
Dec 2021
-$406.29 M(-618.5%)
-$299.47 M(+1666.4%)
-$406.29 M(+739.8%)
Sep 2021
-
-$16.95 M(-62.0%)
-$48.38 M(-21.4%)
Jun 2021
-
-$44.62 M(-1.4%)
-$61.52 M(+1129.2%)
Mar 2021
-
-$45.25 M(-177.4%)
-$5.00 M(-106.4%)
Dec 2020
$78.35 M(-1512.0%)
$58.44 M(-294.2%)
$78.35 M(-176.1%)
Sep 2020
-
-$30.09 M(-352.9%)
-$102.91 M(+223.5%)
Jun 2020
-
$11.90 M(-68.8%)
-$31.81 M(-949.0%)
Mar 2020
-
$38.11 M(-131.0%)
$3.75 M(-167.5%)
Dec 2019
-$5.55 M(-322.6%)
-$122.82 M(-399.6%)
-$5.55 M(-104.3%)
Sep 2019
-
$41.00 M(-13.6%)
$128.08 M(+4.8%)
Jun 2019
-
$47.46 M(+64.7%)
$122.27 M(+81.9%)
Mar 2019
-
$28.81 M(+166.6%)
$67.21 M(+2595.8%)
Dec 2018
$2.49 M(-101.5%)
$10.81 M(-69.3%)
$2.49 M(-101.6%)
Sep 2018
-
$35.19 M(-562.6%)
-$157.30 M(-3.0%)
Jun 2018
-
-$7.61 M(-78.8%)
-$162.21 M(-20.4%)
Mar 2018
-
-$35.90 M(-75.9%)
-$203.90 M(+24.5%)
Dec 2017
-$163.73 M(+113.3%)
-$148.99 M(-592.0%)
-$163.73 M(-2698.5%)
Sep 2017
-
$30.28 M(-161.4%)
$6.30 M(-140.0%)
Jun 2017
-
-$49.29 M(-1255.7%)
-$15.74 M(-147.5%)
Mar 2017
-
$4.26 M(-79.7%)
$33.12 M(-143.1%)
Dec 2016
-$76.77 M(-1403.8%)
$21.05 M(+155.2%)
-$76.77 M(-31.8%)
Sep 2016
-
$8.25 M(-1995.6%)
-$112.57 M(+12.0%)
Jun 2016
-
-$435.00 K(-99.6%)
-$100.52 M(+12.5%)
Mar 2016
-
-$105.62 M(+615.8%)
-$89.31 M(-1616.9%)
Dec 2015
$5.89 M(-117.9%)
-$14.76 M(-172.7%)
$5.89 M(-82.7%)
Sep 2015
-
$20.29 M(+88.4%)
$34.13 M(+107.3%)
Jun 2015
-
$10.77 M(-203.4%)
$16.46 M(-9245.0%)
Mar 2015
-
-$10.42 M(-177.3%)
-$180.00 K(-99.5%)
Dec 2014
-$32.95 M(-31.2%)
$13.48 M(+413.0%)
-$32.95 M(-25.8%)
Sep 2014
-
$2.63 M(-144.8%)
-$44.42 M(-6.2%)
Jun 2014
-
-$5.87 M(-86.4%)
-$47.37 M(+13.9%)
Mar 2014
-
-$43.19 M(-2241.3%)
-$41.58 M(-13.1%)
Dec 2013
-$47.87 M
$2.02 M(-720.6%)
-$47.87 M(-5.1%)
Sep 2013
-
-$325.00 K(+306.3%)
-$50.43 M(+0.3%)
DateAnnualQuarterlyTTM
Jun 2013
-
-$80.00 K(-99.8%)
-$50.27 M(-1.3%)
Mar 2013
-
-$49.48 M(+9066.5%)
-$50.91 M(+3503.0%)
Dec 2012
-$1.41 M(+70.5%)
-$539.80 K(+222.3%)
-$1.41 M(-1.2%)
Sep 2012
-
-$167.50 K(-76.8%)
-$1.43 M(+9.9%)
Jun 2012
-
-$721.50 K(-4666.5%)
-$1.30 M(+113.5%)
Mar 2012
-
$15.80 K(-102.8%)
-$609.70 K(-26.4%)
Dec 2011
-$828.50 K(+28.2%)
-$557.00 K(+1328.2%)
-$828.50 K(+37.6%)
Sep 2011
-
-$39.00 K(+32.2%)
-$602.20 K(-3.5%)
Jun 2011
-
-$29.50 K(-85.5%)
-$623.80 K(-10.9%)
Mar 2011
-
-$203.00 K(-38.6%)
-$700.40 K(+8.4%)
Dec 2010
-$646.50 K(-55.7%)
-$330.70 K(+445.7%)
-$646.40 K(-26.5%)
Sep 2010
-
-$60.60 K(-42.9%)
-$879.10 K(-9.3%)
Jun 2010
-
-$106.10 K(-28.8%)
-$969.40 K(-24.9%)
Mar 2010
-
-$149.00 K(-73.6%)
-$1.29 M(-11.6%)
Dec 2009
-$1.46 M(+26.0%)
-$563.40 K(+273.4%)
-$1.46 M(+27.0%)
Sep 2009
-
-$150.90 K(-64.7%)
-$1.15 M(-19.8%)
Jun 2009
-
-$427.80 K(+34.1%)
-$1.43 M(+12.6%)
Mar 2009
-
-$319.00 K(+26.4%)
-$1.27 M(+9.8%)
Dec 2008
-$1.16 M(-51.0%)
-$252.40 K(-42.0%)
-$1.16 M(-40.2%)
Sep 2008
-
-$435.40 K(+63.1%)
-$1.94 M(-0.1%)
Jun 2008
-
-$267.00 K(+30.2%)
-$1.94 M(-19.4%)
Mar 2008
-
-$205.00 K(-80.2%)
-$2.41 M(+1.9%)
Dec 2007
-$2.37 M(+548.4%)
-$1.03 M(+136.6%)
-$2.37 M(+64.1%)
Sep 2007
-
-$436.70 K(-40.5%)
-$1.44 M(+24.2%)
Jun 2007
-
-$734.50 K(+356.5%)
-$1.16 M(+138.5%)
Mar 2007
-
-$160.90 K(+47.2%)
-$486.80 K(+33.4%)
Dec 2006
-$364.80 K(+4.0%)
-$109.30 K(-30.0%)
-$364.80 K(+38.8%)
Sep 2006
-
-$156.20 K(+158.6%)
-$262.90 K(+29.3%)
Jun 2006
-
-$60.40 K(+55.3%)
-$203.40 K(-21.5%)
Mar 2006
-
-$38.90 K(+425.7%)
-$259.10 K(-26.2%)
Dec 2005
-$350.90 K(+53.9%)
-$7400.00(-92.3%)
-$350.90 K(-23.6%)
Sep 2005
-
-$96.70 K(-16.7%)
-$459.00 K(+18.9%)
Jun 2005
-
-$116.10 K(-11.2%)
-$386.20 K(+22.0%)
Mar 2005
-
-$130.70 K(+13.2%)
-$316.60 K(+38.9%)
Dec 2004
-$228.00 K(<-9900.0%)
-$115.50 K(+383.3%)
-$227.90 K(+328.4%)
Sep 2004
-
-$23.90 K(-48.6%)
-$53.20 K(+21.2%)
Jun 2004
-
-$46.50 K(+10.7%)
-$43.90 K(+4.5%)
Mar 2004
-
-$42.00 K(-170.9%)
-$42.00 K(<-9900.0%)
Dec 2003
$0.00(0.0%)
$59.20 K(-505.5%)
$0.00(-100.0%)
Sep 2003
-
-$14.60 K(-67.3%)
-$34.20 K(+74.5%)
Jun 2003
-
-$44.60 K(<-9900.0%)
-$19.60 K(<-9900.0%)
Mar 2003
-
$0.00(-100.0%)
$0.00(0.0%)
Dec 2002
$0.00(0.0%)
$25.00 K(>+9900.0%)
$0.00(-100.0%)
Sep 2002
-
$0.00(-100.0%)
-$25.00 K(0.0%)
Jun 2002
-
-$25.00 K(<-9900.0%)
-$25.00 K(<-9900.0%)
Mar 2002
-
$0.00
$0.00
Dec 2001
$0.00
-
-

FAQ

  • What is Halozyme Therapeutics annual cash flow from investing activities?
  • What is the all time high annual CFI for Halozyme Therapeutics?
  • What is Halozyme Therapeutics annual CFI year-on-year change?
  • What is Halozyme Therapeutics quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Halozyme Therapeutics?
  • What is Halozyme Therapeutics quarterly CFI year-on-year change?
  • What is Halozyme Therapeutics TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Halozyme Therapeutics?
  • What is Halozyme Therapeutics TTM CFI year-on-year change?

What is Halozyme Therapeutics annual cash flow from investing activities?

The current annual CFI of HALO is -$262.72 M

What is the all time high annual CFI for Halozyme Therapeutics?

Halozyme Therapeutics all-time high annual cash flow from investing activities is $78.35 M

What is Halozyme Therapeutics annual CFI year-on-year change?

Over the past year, HALO annual cash flow from investing activities has changed by -$165.81 M (-171.10%)

What is Halozyme Therapeutics quarterly cash flow from investing activities?

The current quarterly CFI of HALO is $29.48 M

What is the all time high quarterly CFI for Halozyme Therapeutics?

Halozyme Therapeutics all-time high quarterly cash flow from investing activities is $58.44 M

What is Halozyme Therapeutics quarterly CFI year-on-year change?

Over the past year, HALO quarterly cash flow from investing activities has changed by $0.00 (0.00%)

What is Halozyme Therapeutics TTM cash flow from investing activities?

The current TTM CFI of HALO is -$262.72 M

What is the all time high TTM CFI for Halozyme Therapeutics?

Halozyme Therapeutics all-time high TTM cash flow from investing activities is $128.08 M

What is Halozyme Therapeutics TTM CFI year-on-year change?

Over the past year, HALO TTM cash flow from investing activities has changed by $0.00 (0.00%)